Last updated: 2026-09-16 10:31:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
SpyGlass Pharma, Inc. (SGP) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $28.85, with a market capitalisation of $958.62M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17.06 to $32.44. This page covers its latest market performance, valuation, price trends and company information.
$958.62M | |
$28.57 | |
$35.15 | |
$11.97 | |
$28.66 | |
124.56K | |
120.54K | |
-- | |
$32.44 | |
$17.06 | |
-- | |
-- |
SpyGlass Pharma, Inc. (SGP) is trading at $28.10 in pre-market trading as of 2026-09-15 23:31:00, down 1.95% ($0.56) from the previous close of $28.66
Pre-market trading shows how investors are pricing SGP before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, SpyGlass Pharma, Inc. (SGP) moved from $28.94 to $28.85, representing a decline of 0.32% ($0.09).
The stock traded between $27.00 and $30.05 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 112.55 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 76.6%
SGP is currently trading at $28.85, placing it 76.6% of the way from its 52-week low of $17.06 to its 52-week high of $32.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 65 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SpyGlass Pharma, Inc. (SGP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.